Tinea Corporis Market Research Report -Forecast till 2030

Tinea Corporis Market Research Report: By drug type (antifungals and others), by diagnosis (physical exam, imaging test, and others), by treatment (antifungal shampoos and others), by end-users (hospital pharmacies and others)- Forecast till 2030

ID: MRFR/Pharma/5373-HCR | February 2023 | Region: Global | 90 Pages         

Tinea Corporis Market Speak to Analyst Request a Free Sample

Tinea Corporis Market Scenario:



The Tinea corporis market is anticipated to reach USD 18.05 Billion by 2030 at 3.10% CAGR during the forecast period 2022-2030.



Tinea corporis is a fungal infection that is caused by tinea rubrum, trichophyton mentagrophytes and epidermophyton floccosum fungi. This fungal infection mainly occurs in humid climatic condition. It is also known as ringworm infection. Tinea corporis infection occurs mostly on arms, legs or can also occur on different parts of body. Tinea corporis is contagious infection which can spread from one person to other hence it is important not to share towel, flannels, bathmats with another person.

The tinea corporis market is expected to see the growth in upcoming year due to entry of new drug product in market for treatment. Many key players in market are engaged in development of new drug product for tinea corporis treatment. The prevalence of tinea infection is higher in humid climatic condition. Increasing incidences of fungal diseases and increasing prevalence of various skin disorders are some of the key factors responsible for the market growth. Various other factors such as increasing awareness regarding skin infection, new drug development, are also driving the global tinea corporis market.

However certain factors that can hamper the growth of this market in near future are lack of awareness regarding fungal disease, adverse side effect due to antifungal drugs and alternative treatment plans. 

Tinea Corporis Market Key players:


Some of the key players in the global tinea corporis market are Taro Pharmaceuticals., Inc., Teva Pharmaceuticals, Inc., Glenmark Pharmaceuticals Inc, Breckenridge Pharmaceutical, Inc., NorthStar Rx LLC, Aurobindo Pharma Limited, and Camber Pharmaceuticals, Inc., AvKare, Inc., Novartis AG, Sebela Pharmaceuticals, Inc., Bayer AG, Blueberry Therapeutics Ltd, Perrigo Company.


Intended Audience



  • Manufacturers and Suppliers

  • Hospitals and Clinics

  • Laboratories and Associations

  • Research Institutes

  • Dermatology Clinics


Market Segmentation:


Global tinea corporis market is segmented into drug type, diagnosis, treatment and end-users. Tinea corporis market on basis of drug types is segmented into antifungals, steroids and anti-infective combinations.


Based on diagnosis tinea corporis market is segmented into physical exam, imaging tests. Imaging test is further sub-segmented into wood lamp (black light) examination, microscopy using potassium hydroxide (KOH), fungal culture, skin biopsy and others.


Based on treatment tinea corporis market is segmented into antifungal shampoos, antifungal creams, drugs and others. On basis of end-user market is further segmented into hospital pharmacies, drug stores, online pharmacies, dermatology hospitals, medical research centres, academic institutes others.\


Global Tinea Corporis Market by Drug Type



  • Antifungals

  • Steroids

  • Anti-Infective Combinations


Global Tinea Corporis Market, by Diagnosis



  • Physical Exam


  • Imaging Tests

    • Wood lamp (black light) examination

    • Microscopy using potassium hydroxide (KOH)

    • Fungal culture

    • Skin biopsy

    • Others




Global Tinea Corporis Market, by Treatment



  • Antifungal shampoos

  • Antifungal creams

  • Drugs

  • Others


Global Tinea Corporis Market, by End-Users



  • Hospital Pharmacies

  • Drug Stores

  • Online Pharmacies

  • Dermatology hospitals

  • Others


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The tinea corporis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of the tinea corporis market.  


The European tinea corporis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The tinea corporis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The tinea corporis market in the Middle East & Africa has been segmented into the Middle East and Africa.


Global Tinea Corporis Market Share (%), by Region, 2017 Tinea Corporis Market Share


Source: Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American association of neurological surgeon


Regional Market Summary


Geographically, the America holds the highest market share for tinea corporis market and the reason being many market players are engaged in development of new drug product innovation, and as this infection is more prone to humid climatic condition there is an increasing prevalence of fungal infection in this region. Whereas increasing awareness of fungal disease and rising healthcare expenditure by the government are some of the factors responsible for growth of market in this region


Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of fungal infection, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region. 


Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of fungal infection, changing lifestyle, increase in population, increasing healthcare expenditure by government are some of the factor responsible for market growth in this region. 


Global Tinea Corporis Market, by Region




  • Americas


    • North America

      • US

      • Canada



    • South America




  • Europe


    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe




  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia Pacific




  • The Middle East & Africa

    • Middle East

    • Africa





Report Scope:

Report Attribute/Metric Details
  Market Size   2030 .USD 18.05 Billion
  CAGR   3.10% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Type, Diagnosis, Treatment and End-Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Taro Pharmaceuticals., Inc., Teva Pharmaceuticals, Inc., Glenmark Pharmaceuticals Inc, Breckenridge Pharmaceutical, Inc., NorthStar Rx LLC, Aurobindo Pharma Limited, and Camber Pharmaceuticals, Inc., AvKare, Inc., Novartis AG, Sebela Pharmaceuticals, Inc., Bayer AG, Blueberry Therapeutics Ltd, Perrigo Company.
  Key Market Opportunities   Entry of new drug product in market for treatment.
  Key Market Drivers

  • Increasing incidences of fungal diseases and increasing prevalence of various skin disorders
  • Increasing awareness regarding skin infection, new drug development


  • Speak to Analyst Ask for Customization